Cargando…

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration

Detalles Bibliográficos
Autores principales:	Egilman, Alexander, Wallach, Joshua D., Puthumana, Jeremy, Zhang, Audrey D., Schwartz, Jason L., Ross, Joseph S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Concise Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205312/ https://www.ncbi.nlm.nih.gov/pubmed/34131876 http://dx.doi.org/10.1007/s11606-021-06943-x

Ejemplares similares

Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010–2020
por: Zhang, Audrey D., et al.
Publicado: (2021)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval
por: Wallach, Joshua D., et al.
Publicado: (2021)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

A Structured Preapproval and Postapproval Comparative Study Design Framework to Generate Valid and Transparent Real‐World Evidence for Regulatory Decisions
por: Gatto, Nicolle M., et al.
Publicado: (2019)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015
por: MacGregor, Andrea, et al.
Publicado: (2020)

Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
por: Wallach, Joshua D., et al.
Publicado: (2018)

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
por: Pease, Alison M, et al.
Publicado: (2017)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
por: Wallach, Joshua D., et al.
Publicado: (2019)

Best practices in designing preapproval information engagements for US health care decision makers
por: Dodda, Sai, et al.
Publicado: (2023)

Analysis of US Food and Drug Administration Breast Implant Postapproval Studies Finding an Increased Risk of Diseases and Cancer: Why the Conclusions Are Unreliable
por: Swanson, Eric
Publicado: (2019)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Availability of Investigational Medicines Through the US Food and Drug Administration’s Expanded Access and Compassionate Use Programs
por: Puthumana, Jeremy, et al.
Publicado: (2018)

The progress of postapproval clinical studies on Sabin IPV
por: Shi, Li, et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023)

Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing
por: Harrigan, James J., et al.
Publicado: (2020)

Six‐month outcomes in postapproval HeartMate3 patients: A single‐center US experience
por: Bansal, Aditya, et al.
Publicado: (2022)

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018
por: Omae, Kenji, et al.
Publicado: (2022)

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
por: Long, Aaron S., et al.
Publicado: (2021)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Strengthening postapproval oversight in research ethics committees: Challenges and solutions
por: Shetty, Yashashri Chandrakant, et al.
Publicado: (2023)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Results of the combined U.S. multicenter postapproval study of the Nit‐Occlud PDA device for percutaneous closure of patent ductus arteriosus
por: Kobayashi, Daisuke, et al.
Publicado: (2018)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Inpatient antibiotic utilization in the Veterans’ Health Administration during the coronavirus disease 2019 (COVID-19) pandemic
por: Dieringer, Thomas D., et al.
Publicado: (2020)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017
por: Egilman, Alexander C., et al.
Publicado: (2019)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications
por: Hong, Kyungwan, et al.
Publicado: (2022)

Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals
por: Downing, Nicholas S., et al.
Publicado: (2016)

DuraSeal Exact Is a Safe Adjunctive Treatment for Durotomy in Spine: Postapproval Study
por: Kim, Kee D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cb8qdud65nn8b7ti0d6ja2517s